Perseus Proteomics Inc. (4882.T)
JPY 414.0
(5.08%)
JPY 414.0
(5.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -894.72 Million JPY | -28.23% |
| 2022 | -697.76 Million JPY | -47.77% |
| 2021 | -472.19 Million JPY | -14.68% |
| 2020 | -411.74 Million JPY | 49.29% |
| 2019 | -812 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -221 Million JPY | -7.68% |
| 2023 Q2 | -209.68 Million JPY | 10.61% |
| 2023 Q1 | -234.56 Million JPY | -5.66% |
| 2023 Q4 | -205.23 Million JPY | 16.32% |
| 2023 Q3 | -245.24 Million JPY | -16.96% |
| 2023 FY | -894.72 Million JPY | -28.23% |
| 2022 Q3 | -169 Million JPY | -11.9% |
| 2022 FY | -697.76 Million JPY | -47.77% |
| 2022 Q4 | -222 Million JPY | -31.36% |
| 2022 Q2 | -151.03 Million JPY | 0.0% |
| 2021 FY | -472.19 Million JPY | -14.68% |
| 2020 FY | -411.74 Million JPY | 49.29% |
| 2019 FY | -812 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 95.84 Billion JPY | 100.934% |
| Astellas Pharma Inc. | 124.6 Billion JPY | 100.718% |
| Chugai Pharmaceutical Co., Ltd. | 439.17 Billion JPY | 100.204% |
| Ono Pharmaceutical Co., Ltd. | 163.1 Billion JPY | 100.549% |
| Santen Pharmaceutical Co., Ltd. | 38.54 Billion JPY | 102.321% |
| JCR Pharmaceuticals Co., Ltd. | 7.53 Billion JPY | 111.879% |
| Daiichi Sankyo Company, Limited | 211.58 Billion JPY | 100.423% |
| Otsuka Holdings Co., Ltd. | 139.61 Billion JPY | 100.641% |